The role of procalcitonin in acute heart failure patients

Martin Möckel1,2*, Julia Searle2 and Alan Maisel3

1Department of Cardiology, Charité – Universitätsmedizin Berlin, Berlin, Germany; 2Division of Emergency and Acute Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany; 3University of California San Diego and VA Medical Center, San Diego, CA, USA

Abstract

Acute dyspnoea is a common chief complaint in the emergency department and is mainly caused by cardiac and pulmonary underlying diagnoses. In patients with acute heart failure (AHF), an early initiation of adequate therapy is important to improve patient outcome. Clinical differentiation of pulmonary and cardiac underlying causes and of concomitant pathologies determines which therapeutic strategy is chosen.

Procalcitonin is a marker of bacterial infection, which is markedly increased in AHF patients with concomitant bacterial infection and thus has the potential to guide the early initiation of adequate antibiotic therapy. The IMPACT-EU trial is a multicenter randomized controlled trial designed to test this hypothesis.

This mini-review summarizes the current literature on procalcitonin in AHF and explains the design of the IMPACT-EU trial.

Keywords  Procalcitonin; Acute heart failure; Bacterial infection; Inflammation; Antibiotic therapy

Introduction

Acute dyspnoea is one of the most common and, more importantly, most detrimental symptoms in emergency medicine, as it is associated with a high mortality. Acute dyspnoea can be caused by an array of underlying diagnoses, including mainly cardiac and pulmonary diseases.1 Independent of the underlying pathology, a fast containment of the most likely differential diagnoses and consequently, a fast and adequate initiation of therapy in the emergency department (ED) can be life-saving. Additionally, identification of high-risk patients, who most profit from intensive monitoring and therapy, is important to support treatment and management decisions.

Acute heart failure (AHF) is one of the most important differential diagnoses in these patients. Recent guidelines23 define AHF as a time critical disease comparable to acute coronary syndrome and support the concept to identify the underlying trigger factors or precipitants as soon as possible.

Increasingly, patients in emergency medicine are characterized by old age and multi-morbidity and rarely present with a single disease and its typical clinical pattern. The challenge in AHF is to identify the underlying cause or precipitant, i.e. the most important of a number of co-existing diagnoses, which requires immediate attention and intervention. Maisel et al. were recently able to show that adequate prescription of antibiotics in heart failure influences patient outcome. Patients with bacterial infection, who did not receive an antibiotic, had an impaired prognosis. Surprisingly, also patients without bacterial infection who did receive an antibiotic had a worse outcome than patients without antibiotic therapy.2 Procalcitonin (PCT) is a precursor peptide of the hormone calcitonin, and levels increase particularly following bacterial infection. A more rapid rise and fall in blood with a very strong signal with 105-fold increase as compared with other molecules like C-reactive protein showing only a 10- to 100-fold increase is observed. The half-life is around 24 h, and the molecule is stable in vivo and in vitro. Therefore, PCT is a marker of bacterial infection, and recent evidence suggests that it can be used to guide decision-making with respect to antibiotic therapy in patients with AHF by identifying patients with concomitant or triggering bacterial infection. On the other hand, evidence suggests that inflammation may be an important pathophysiological factor in heart failure, which may impact patient prognosis. PCT is therefore studied from two perspectives, as a prognostic marker in heart failure as well as a guiding biomarker for adequate medical therapy. This article summarizes the current evidence to help clinicians in their judgement and use of PCT in routine practice.
Procalcitonin as a prognostic marker in heart failure

It has long been known that severe or worsening heart failure is associated with systematic inflammation. Levine et al. published their article on ‘Elevated Circulating Levels of Tumor Necrosis Factor in Severe Chronic Heart Failure’ over 25 years ago in an attempt to evaluate the pathogenesis of cardiac cachexia. Interestingly, they found that tumor necrosis factor alpha levels were markedly increased in patients with end-stage heart failure and renal impairment without being correlated to cardiac output or ventricular filling pressure, thus indicating prognosis rather than cardiac function. Several studies were since able to show that increased cytokine levels were related to a poor prognosis in patients with heart failure.4–7

Anker et al. developed the hypothesis that the inflammation in AHF might be caused by mesenteric congestion, leading to bacterial translocation from the intestinal lumen into the bloodstream, thereby causing endotoxemia and, consequently, immune activation.8 In this context, PCT was first investigated by Niebauer et al. who were able to show that endotoxin and inflammatory cytokine levels increased during the oedematous state of AHF. PCT was reported to show higher levels in patients with oedematous heart failure as compared with patients with compensated heart failure and to controls without heart failure.9 Mollar et al. studied the role of PCT in patients with heart failure and confirmed absence of bacterial infection to evaluate the role of PCT in patients with AHF admitted to an ED. Their results support the role of PCT as an indicator of endotoxin-immune activation, as PCT levels correlated with markers of inflammation, including endotoxin, as well as markers of venous congestion.10

A large study from China compared PCT levels in patients with isolated AHF, patients with isolated bacterial infections, patients with AHF complicated by bacterial infection, and healthy controls. Their findings confirm a role of PCT in AHF in the absence of bacterial infection, as patients with isolated AHF compared with healthy controls had higher PCT levels. Patients with isolated bacterial infection had lower PCT levels than patients with bacterial infection complicated by heart failure.11

Recently, Boulogne et al. investigated biomarkers of inflammation and of mechanical stress in patients with acute and chronic heart failure. Patients with active or recent infection, inflammatory disease, or active cancer were excluded. The authors were able to show that markers of inflammation and of mechanical stress were highest in patients with AHF,
but whilst markers of mechanical stress decreased with clinical improvement, markers of inflammation remained high for up to 1 month after re-compensation. Interestingly, PCT levels did not differ between patients with AHF and chronic heart failure. PCT levels were above 0.05 ng/mL but below the cut-off for systemic infection (<0.50 ng/mL) in the majority of patients.12

Even though plenty of evidence suggests the important role of inflammation in the pathogenesis of AHF and in the prognosis of heart failure patients, the prognostic value of PCT in patients with isolated heart failure remains unclear, as evidence is sparse. Maisel et al. reported a significant association of PCT with the 90-day mortality of ED dyspnoea patients diagnosed with AHF with a reduced survival rate of patients in the fifth PCT quintile (>0.21 ng/mL) of 80.5% as opposed to 92% for patients in the first PCT quintile (<0.05 ng/mL),2 but this included patients with concomitant pulmonary infection. In a trial by Travaglini et al., PCT was a modest predictor for 30- and 90-day mortality in ED patients with acute dyspnoea, but sub-analysis revealed that this was true for patients without heart failure only.13

Villanueva et al. on the other hand reported increased long-term mortality rates of AHF patients with increased PCT levels independent of white blood cell count, C-reactive protein, endotoxin, and different interleukin levels.14 In a trial by Loncar et al., PCT had a significant but modest prognostic value in AHF patients without clinical signs of infection at admission.15

In the PROTECT trial, which included AHF patients without clinical signs of infection, patients with elevated PCT levels had a higher 30-day mortality and were more often classified as treatment failures, although they did not differ in disease severity.16

### Table 1
Overview of the different PCT cut-off values and of mean/median PCT values in different studies and study groups

| Publication                  | PCT-assay                | Patients                                              | Predetermined cut-off values or PCT results                                                                 |
|------------------------------|--------------------------|-------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| Bouligne et al.12            | Kryptor, Thermo Fisher   | Patients with AHF and CHF                              | AHF admission value median: 0.14 (0.09–0.21) ng/mL CHF admission value median: 0.13 (0.10–0.21) ng/mL Use of antibiotics Discouraged: PCT <0.1 ng/mL (strong advice) or <0.25 ng/mL (advice) Encouraged: PCT >0.5 ng/mL (strong advice) or ≥0.25 ng/mL (advice) |
| Christ-Crain et al.18        | Kryptor, Thermo Fisher   | Patients with LRTI                                     | Significant elevation of PCT was considered present when baseline levels exceeded 0.20 ng/mL Patients with levels <0.20 ng/mL were considered to have low PCT levels. Baseline PCT levels ≥0.20 ng/mL in 6% of analysed patients. |
| Demissei et al.16            | Alere                    | Patients with AHF without clinical signs of infection  | AHF patients: PCT concentration >0.21 ng/mL (upper quintile): Significantly worse survival if not treated with antibiotics. PCT concentrations between 0.05 and 0.21 ng/mL: Antibiotic treatment did not affect survival. PCT values <0.05 ng/mL; Increased mortality if they were treated with antibiotics All patients: Patients in the first quintile (PCT <0.05 ng/mL): 90-day survival rate 92.0%, patients in the fifth quintile (PCT >0.21 ng/mL): 90-day survival rate 80.5% Mean PCT 0.06 (±0.06) ng/mL |
| Maisel et al.2               | Kryptor, Thermo Fisher   | Patients with acute dyspnoea                           | Use of antibiotics Discouraged: PCT <0.1 ng/mL (strong advice) or <0.25 ng/mL (advice) Encouraged: PCT ≥0.5 ng/mL (strong advice) or ≥0.25 ng/mL (advice) |
| Mollar et al.10              | Elecsys BRAHMS PCT       | Patients with AHF without clinical signs of infection  | Use of antibiotics |
| Schütz et al. ProHosp sub-analysis21 | Kryptor, Thermofisher   | Patients with LRTI and AHF                            | |
| Travaglini et al.13          | Kryptor, Thermofisher    | Patients with acute dyspnoea                           | |
| Villanueva et al.14          | Elecsys BRAHMS PCT       | Patients with AHF without clinical signs of infection  | |
| Wang et al.11                | Cobas, Roche             | Comparison of four study groups                        | |

AHF, acute heart failure; CHF, chronic heart failure; HF, heart failure; LRTI, lower respiratory tract infection; PCT, procalcitonin.

Kryptor, Thermofisher: Normal value according to manufacturer PCT <0.05 ng/mL, diagnosis of systemic infection PCT >0.50 ng/mL.
Procalcitonin as a marker to guide antibiotic therapy in acute heart failure

The idea of using PCT as a marker to guide antibiotic treatment in patients with AHF stems from studies testing PCT in patients with lower respiratory tract infections (LRTI), all showing a reduction of antibiotic prescriptions in PCT-guided patient management. In times of increasing antibiotic oversubscription and of antibiotic resistance, this is an extremely valuable achievement. Christ-Crain et al. used PCT to guide antibiotic treatment in a cohort of patients presenting to the ED with LRTI. They were able to show that confirmation or exclusion of bacterial infection with PCT before treatment initiation led to a significant reduction of antibiotic prescriptions. In the ProHosp Trial, a large randomized clinical trial also set in EDs and recruiting patients with LRTI, the mean duration of antibiotic exposure and, consequently, the rates of antibiotic-related side effects were significantly lower in the PCT-guided group. Notably, the rate of adverse outcomes did not differ between the two study groups.

In 2012, Maisel et al. published a sub-analysis of the BACH trial, a large multicenter diagnostic biomarker study in ED patients with acute dyspnea. This analysis evaluated the diagnostic value of PCT in patients with a diagnosis of AHF and surprisingly not only showed that patients with confirmed AHF and increased PCT levels had a worse outcome if they did not receive antibiotic treatment but also that patients with confirmed AHF and low PCT levels had a worse outcome if they—inadequately—received antibiotic treatment.

Two years later, Schuetz et al. published a sub-analysis from the above-mentioned ProHOSP trial, including only the 233 patients with heart failure. As was already reported in the original trial, the primary endpoint (mortality and intensive care unit admission) did not significantly differ between the two study groups (PCT-guided vs. standard management), but antibiotic exposure was significantly shorter in the PCT-guided group, as were antibiotic side effects. Even more compelling was that in the group of patients with low PCT (<0.05 ng/mL), patients with PCT guidance had better outcome. Recently, a study on intensive care unit patients confirmed that antibiotic treatment can be safely guided by repetitive PCT measurements and that this transfers into a lower mortality.

The concept to use PCT in heart failure has also been adopted in the recent ESC guidelines. Figure 1 shows how PCT could potentially be used in this setting. Table 1 gives an overview of the different PCT cut-off values and of mean/median PCT values in different studies and study groups.

The IMPACT trial and its future implications

Even though sub-analyses from large trials show promising results for PCT-guided antibiotic therapy in AHF, current evidence is insufficient to allow for implementation into routine clinical practice. The IMPACT-EU study (clinicaltrials.gov; NCT02392689) is a large, multicenter, randomized controlled trial comparing PCT-guided patient management with standard management in the ED. The trial was initiated in 2014 and is ongoing. Patients are enrolled if they present to the...
ED with dyspnoea and suspected heart failure as indicated by increased levels of natriuretic peptides as outlined in Figure 2. A cut-off level of 0.2 ng/mL will be used to support decision on antibiotic therapy initiation in the PCT-guided group, whereas antibiotic treatment is solely based on clinical judgement in the control group.

Patients will be followed up 30 and 90 days after randomization to evaluate the survival status, rehospitalizations, and antibiotic therapy variables.

Conclusions

Evidence regarding the role of PCT in heart failure is promising. Even though data clearly suggests inflammation as an important pathophysiological contributor to severe heart failure, the prognostic value of PCT seems to be related to concomitant infection rather than systemic inflammation in isolated AHF. Adequate therapy is of utmost importance in AHF, and in this respect, correct judgement of the underlying diagnosis in patients presenting with dyspnoea seems to be an important factor determining patient outcome. PCT-guided antibiotic therapy has been proven useful in LRTI and might improve patient outcome by early identification of patients with AHF who will profit from antibiotic treatment. The IMPACT-EU trial is currently testing this hypothesis in a prospective randomized study.

Conflict of interest

M. M. received research grants and lecture fees from Novartis, Thermofisher BRAHMS, and Roche Diagnostics. J. S. reports research grants from Novartis, Thermofisher BRAHMS, and Roche Diagnostics.

The authors declare that the submitted work is original and has not been published before (neither in English nor in any other language) and that the work is not under consideration for publication elsewhere.

Funding

This current work received no funding. The open access fees for the publication were covered by Thermofisher BRAHMS.

References

1. Mockel M, Searle J, Muller R, Slagman A, Storchmann H, Oestereich P, Wyrwich W, Ale-Abaci A, Vollert JO, Koch M, Somasundaram R. Chief complaints in medical emergencies: do they relate to underlying disease and outcome? The Charite Emergency Medicine Study (CHARITEM). *Eur J Emerg Med* 2013; 20: 103–108.

2. Maisel A, Neath SX, Landsberg J, Mueller C, Nowak RM, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clotpton P, Filippatos GS, Di Somma S, Anand I, Ng LL, Daniels LB, Christenson RH, Potocki M, Mc Cord J, Terracciano G, Hartmann O, Bergmann A, Morgenhalter NG, Anker SD. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. *Eur J Heart Fail* 2011; 14: 278–286.

3. Levine B, Kalman J, Mayer L, Fillit HM, McCord J, Terracciano G, Hartmann O, Bergmann A, Morgenhalter NG, Anker SD. Elevated circulating levels of natriuretic peptides as outlined in Figure 2. A cut-off level of 0.2 ng/mL will be used to support decision on antibiotic therapy initiation in the PCT-guided group, whereas antibiotic treatment is solely based on clinical judgement in the control group.

4. Ferrari R, Bachetti T, Confortini R, Ospach C, Febo O, Corti A, Cassani G, Vissoli O. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. *Circulation* 1995; 92: 1479–1486.

5. Rauchhaus M, Doechner W, Francis DP, Davos C, Kemp M, Liebenthal C, Niebauer J, Hooper J, Volk HD, Coats AJ, Anker SD. Plasma cytokine parameters and mortality in patients with chronic heart failure. *Circulation* 2000; 102: 3060–3067.

6. Miettinen RH, Lassus J, Harjola VP, Siirola-Waris K, Melan J, Punnonen KR, Nieminen MS, Laakso M, Pesahkurinen KJ. Prognostic role of pro- and anti-inflammatory cytokines and their polymorphisms in acute decompensated heart failure. *Eur J Heart Fail* 2008; 10: 396–403.

7. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D’Agostino RB. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. *Circulation* 2003; 107: 1486–1491.

8. Anker SD, Egerer KB, Volk HD, Koxx WJ, Poole-Wilson PA, Coats AJ. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. *Am J Cardiol* 1997; 79: 1426–1430.

9. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, Coats AJ, Anker SD. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. *Lancet (London, England)* 1999; 353: 1838–1842.

10. Mollar A, Villanueva MP, Carratala A, Nunez E, Sanchis J, Nunez J. Determinants of procalcitonin concentration in acute heart failure. *Int J Cardiol* 2014; 177: 532–534.

11. Wang W, Zhang X, Ge N, Liu J, Yuan H, Zhang P, Liu W, Wen D. Procalcitonin testing for diagnosis and short-term prognosis in bacterial infection complicated by congestive heart failure: a multicenter analysis of 4,698 cases. *Crit Care* 2014; 18: R4.

12. Boulogne M, Sadoune M, Launay JM, Baudet M, Cohen-Solal A, Logeart D. Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. *Int J Cardiol* 2017; 226: 53–59.

13. Travaglino F, Russo V, De Berardinis B, Numeroso F, Catania P, Cervellin G, Nigra SG, Geraci F, Bressan MA, Guerrini S, Cavazza M, Folli C, Monzani V, Battista S, Mengozi G, Noto P, Carpentieri G, Semplicini A, Stella F, Ingrassia S, Moscatelli P, Giuntini P, Salerno G, Cardelli P, Di Somma S. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERifying DYspnea trial. *Am J Emerg Med* 2014; 32: 334–341.
14. Villanueva MP, Mollar A, Palau P, Carratala A, Nunez E, Santas E, Bodi V, Chorro FJ, Minana G, Blasco ML, Sanchis J, Nunez J. Procalcitonin and long-term prognosis after an admission for acute heart failure. *Eur J Intern Med* 2015; 26: 42–48.

15. Loncar G, Tscholl V, Tahirovic E, Sekularac N, Marx A, Obradovic D, Veskovic J, Lainscak M, von Haehling S, Edelmann F, Arandjelovic A, Apostolovic S, Stanojevic D, Pieske B, Trippel T, Dungen HD. Should procalcitonin be measured routinely in acute decompen-
sated heart failure? *Biomark Med* 2015; 9: 651–659.

16. Demissei BG, Cleland JG, O’Connor CM, Metra M, Ponikowski P, Peereboom M, Davison B, Givertz MM, Bloomfield DM, Dittrich H, van Veldhuisen DJ, Hillege HL, Voors AA, Cotter G. Procalcitonin-based indication of bacte-
rial infection identifies high risk acute heart failure patients. *Int J Cardiol* 2016; 204: 164–171.

17. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, Huber P, Muller B, Tamm M. Antibiotic treatment of exacerbations of COPD: a random-
domized, controlled trial comparing procalcitonin-guidance with standard therapy. *Chest* 2007; 131: 9–19.

18. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencaiy MM, Huber PR, Tamm M, Muller B. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded inter-
vention trial. *Lancet (London, England)* 2004; 363: 600–607.

19. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Regez K, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B. Effect of procalcitonin-based guidelines vs stan-
dard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. *JAMA* 2009; 302: 1059–1066.

20. Schuetz P, Batschwaroff M, Dusemund F, Albrich W, Maurer M, Brutsche M, Huber AR, Muller B. Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study condi-
tions: a post-study survey. *Eur J Clin Microbiol Infect Dis: official publication of the European Society of Clinical Microbiology* 2010; 29: 269–277.

21. Schuetz P, Kurtz A, Grodum E, Haubitz S, Demann D, Vogeli A, Hitz F, Christ-
Crain M, Thomann R, Falconnier C, Hoess C, Henzen C, Marlowe RJ, Zimmerli W, Mueller B. Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute re-
spiratory symptoms: results from the randomized ProHOSP trial. *Int J Cardiol* 2014; 175: 464–472.

22. de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, Loef BG, Dormans T, van Melsen GC, Kluiters YC, Kemperman H, van den Elsen MJ, Schouten JA, Streeflerk JK, Krabbe HG, Kiefth KL, Kluge GH, van Dam VC, van Pelt J, Bormans L, Otten MB, Reidina AC, Endeman H, Twisk JW, van de Garde EM, de Smet AM, Kesecioglu J, Girbes AR, Nijsten MW, de Lange DW. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in criti-
cally ill patients: a randomised, controlled, open-label trial. *Lancet Infect Dis* 2016; 16: 819–827.

23. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats A, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagno-
sis and treatment of acute and chronic heart failure: the Task Force for the diagno-
sis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Devel-
oped with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016; 37: 2129–2200.